Dr. Reddy's Labs announces launch of Nerivio in Spain for migraine treatment

25th May, 2024

Nerivio is planned to be launched in the United Kingdom next June

Hyderabad-based Dr. Reddy's Laboratories has announced the launch of Nerivio in Spain through its subsidiary Reddy Pharma Iberia. Nerivio is a portable Remote Electrical Neuromodulation (NER) device cleared by the United States Food and Drug Administration (USFDA), and CE marked for the treatment of migraine.

This novel wearable device is a drug-free treatment manufactured by Theranica, a prescription digital therapy company that develops advanced neuromodulation devices for migraine and other ailments, based in Israel and the United States.

Currently, migraine is the sixth most prevalent pathology in the world and the second cause of global disability. In Spain, more than 5 million people suffer from migraine (80% women) with a prevalence of 12% (17% in women). 

Nerivio is a non-invasive, prescription-only portable device intended for the acute and prophylactic (preventive) treatment of migraine with or without aura for adults and adolescents aged 12 years and older. Nerivio is placed on the upper arm and controlled by a mobile app. Each device has capacity for 18 treatment sessions of 45 minutes each. For acute treatment, it should be used within 60 minutes of the onset of headache or aura. For prevention, it should be used every other day. Through NER it activates conditioned pain modulation (CPM), specifically by stimulating the nociceptive nerve receptors located under the skin of the arm. This triggers a natural pain-relieving process in the brainstem, causing an overall pain-inhibiting effect.

The launch in Spain is the result of multiple exclusive agreements signed between the European subsidiaries of Dr. Reddy's and Theranica for the marketing and distribution of Nerivio in Germany, Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland and the United Kingdom.

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer